We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00295932
Recruitment Status : Completed
First Posted : February 24, 2006
Last Update Posted : March 14, 2018
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Columbia University
Emory University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center